{
    "eid": "2-s2.0-85065820124",
    "title": "Characteristics and risk factors for antituberculosis drug-induced liver injury in a cohort of patients with cirrhosis in a tertiary referral university teaching hospital in Thailand",
    "cover-date": "2019-04-30",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Biochemistry, Genetics and Molecular Biology (all)",
            "@code": "1300",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "antitubercular agents",
        "drug-induced liver disease",
        "hepatitis",
        "liver cirrhosis",
        "risk factors",
        "tuberculosis"
    ],
    "authors": [
        "Passisd Laoveeravat",
        "Nicha Wongjarupong",
        "Chonlada Phathong",
        "Cameron Hurst",
        "Sombat Treeprasertsuk",
        "Rungsun Rerknimitr",
        "Roongruedee Chaiteerakij"
    ],
    "citedby-count": 2,
    "ref-count": 33,
    "ref-list": [
        "Incidence and prognosis of tuberculosis in patients with cirrhosis of the liver. A danish nationwide population based study",
        "Antitu-bercular therapy in patients with cirrhosis: Challenges and options",
        "Drug-related hepatotoxicity",
        "Hepatotoxic effects of therapies for tuberculosis",
        "The predictors of complications in patients with drug-induced liver injury caused by antimicrobial agents",
        "Pharmacogenetics of isoniazid-induced hepatotoxicity",
        "The incidence, presentation, outcomes, risk of mortality and economic data of drug-induced liver injury from a national database in Thailand: A population-base study",
        "Liver injury during antituberculosis treatment: An 11-year study",
        "Drug-induced hepatotoxicity and tuberculosis in a hospital from the argentinian northeast: Cross-sectional study",
        "Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis",
        "Antituberculosis drugs and hepatotoxicity among hospitalized patients in jos, Nigeria",
        "Prevalence of hepatotoxicity from antituberculosis therapy: A five-year experience from south India",
        "Prevalence, risk factors, management, and treatment outcomes of first-line antituberculous drug-induced liver injury: A prospective cohort study",
        "Incidence of antituber-culosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in dawro zone, south Ethiopia: A cohort study",
        "Hepatotoxicity from antituberculous therapy in the elderly: A systematic review",
        "Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity",
        "Chronic hepatitis b infection and risk of antituberculosis drug-induced liver injury: Systematic review and meta-Analysis",
        "Antituber-culosis drug-induced liver injury in chronic hepatitis and cirrhosis",
        "Hepatotoxicity of anti-Tuberculosis chemotherapy in patients with liver cirrhosis",
        "Clinical characteristics of tuberculosis in patients with liver cirrhosis",
        "Clinical and biochemical profile of tuberculosis in patients with liver cirrhosis",
        "Case definition and phenotype standardization in drug-induced liver injury",
        "Drug induced liver injury network (dilin) prospective study: Rationale, design and conduct",
        "Official American thoracic society/centers for disease control and prevention/infectious diseases society of America clinical practice guidelines: Treatment of drug-susceptible tuberculosis",
        "Antituberculosis drug-related liver dysfunction in chronic hepatitis b infection",
        "Toxic hepatitis with isoniazid and rifampin: A meta-Analysis",
        "Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-Tuberculosis drugs: A prospective four arm observational study in Ethiopian patients",
        "Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome",
        "Outcomes of tb/HIV co-infected patients presenting with antituberculosis drug-induced liver injury",
        "A guide to the management of tuberculosis in patients with chronic liver disease",
        "A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis",
        "Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60028190",
        "affilname": "Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
        "affiliation-country": "Thailand"
    },
    "funding": []
}